Phaseline

Targets › NTRK1

NTRK1 (High affinity nerve growth factor receptor): drug programs, companies and trials

11 programs from 11 companies in 37 trials: 19 Phase 2, 9 Phase 1, 7 Phase 3, 2 Phase 4; Oncology, Neurology, Immunology; next expected readout Jan 2027.

Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand. (UniProt, P04629)

Open in Phaseline: the race on NTRK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheEntrectinib (RXDX-101)
Neurotrophic tyrosine kinase receptor inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; ALK tyrosine kinase receptor inhibitor
NTRK1, NTRK2, NTRK3, ROS1, ALKPhase 3Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Breast Cancer; Solid Tumors …Jan 2027
Bristol-Myers SquibbRepotrectinib
Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor
NTRK1, NTRK2, ROS1, NTRK3, CD74Phase 3Carcinoma, Non-Small-Cell LungFeb 2027
Nuvation BioTaletrectinib
Proto-oncogene tyrosine-protein kinase ROS inhibitor; Neurotrophic tyrosine kinase receptor inhibitor
ROS1, NTRK1, NTRK2, NTRK3Phase 3Non Small Cell Lung Cancer; Non-small Cell Lung Cancer (NSCLC)Jun 2027
Dompé FarmaceuticiCenegermin
Neurotrophic tyrosine kinase receptor agonist
NTRK1, NTRK2, NTRK3Phase 3Non-Arteritic Anterior Ischemic Optic Neuropathy; Persistent Corneal Epithelial Defect; Dry EyeSep 2027
Benedetto FalsiniCHF6467
Nerve growth factor (NGF) agonist; binds trkA (NTRK1) receptor with high affinity and p75N
NGFR, NTRK1Phase 2Optic Pathway GliomaJun 2027
Teligene USTL118
NTRK fusion inhibitor
NTRK1, NTRK2, NTRK3Phase 2Solid TumorDec 2027
Xuanzhu BiopharmaceuticalXZP-5955 tablets
NTRK and ROS1 fusion inhibitor
NTRK1, NTRK2, NTRK3, ROS1Phase 1Locally Advanced or Metastatic Solid TumorsJun 2027
Turning Point TherapeuticsRepotrectinib (TPX-0005)
Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor
NTRK1, NTRK2, ROS1, NTRK3, CD74Phase 1Locally Advanced Solid Tumors; NSCLC; NSCLC Stage IV; Advanced CancerSep 2027
VM OncologyVMD-928
TrkA inhibitor
NTRK1Phase 1Head and Neck CarcinomaDec 2027
Cullgen (Shanghai),IncCG001419
NTRK inhibitor
NTRK1, NTRK2, NTRK3Phase 1Solid Tumors Harboring NTRK FusionAug 2030
BayerLarotrectinib (BAY2757556)
Neurotrophic tyrosine kinase receptor inhibitor
NTRK1, NTRK2, NTRK3Phase 1Solid Tumors Harboring NTRK Fusion; Advanced Malignant Solid Neoplasm; Advanced Lymphoma; Central Nervous System Neoplasm …–

Conditions

Non Small Cell Lung Cancer (3) Non-Small Cell Lung Cancer (2) Carcinoma, Non-Small-Cell Lung (2) Solid Tumors (2) Haematological Malignancy (2) Solid Tumors Harboring NTRK Fusion (2) Locally Advanced Solid Tumors (2) Locally Advanced or Metastatic Solid Tumors (1) Non-Arteritic Anterior Ischemic Optic Neuropathy (1) Persistent Corneal Epithelial Defect (1) Dry Eye (1) Non-small Cell Lung Cancer (NSCLC) (1)

Modalities

small molecule (9), protein or peptide (1), mixed (1)

Companies

Xuanzhu Biopharmaceutical (1) Dompé Farmaceutici (1) Nuvation Bio (1) Roche (1) Cullgen (Shanghai),Inc (1) Turning Point Therapeutics (1) Bristol-Myers Squibb (1) VM Oncology (1) Benedetto Falsini (1) Teligene US (1) Bayer (1)

Related targets

NTRK2 (9) NTRK3 (9) ROS1 (5) CD74 (2) ALK (1) NGFR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.